Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant...

Area of Science:

• Oncology
• Transplant Medicine
• Pharmacology

Background:

• Solid organ transplant recipients face a worse cancer prognosis compared to the general population.
• Challenges in cancer treatment include graft toxicity, rejection risk, drug interactions, organ dysfunction, and patient comorbidities.
• Immunotherapy, particularly checkpoint inhibitors, introduces additional risks of life-threatening graft rejection.

Purpose of the Study:

• To provide a review of general principles for managing cancer in solid organ transplant recipients.
• To aid oncologists and transplant physicians in multidisciplinary decision-making for cancer therapy.
• To address the complexities of chemotherapy, targeted therapy, and immunotherapy in this patient population.

Main Methods:

• Review of existing literature and clinical guidelines.
• Analysis of risks and benefits associated with various anticancer treatments.
• Discussion of pharmacokinetic and pharmacodynamic drug interactions.
• Consideration of organ function and patient-specific factors.

Main Results:

• No anticancer drugs are universally safe or unsafe; selection requires individualized risk/benefit assessment.
• Awareness of drug-to-drug interactions and potential for drug overexposure in renal or hepatic dysfunction is critical.
• Checkpoint inhibitors pose a significant risk of graft rejection in transplant recipients.

Conclusions:

• Optimal anticancer regimen selection in solid organ transplant recipients necessitates a thorough risk/benefit evaluation.
• Multidisciplinary collaboration between oncologists and transplant physicians is essential for effective patient management.
• Careful consideration of drug interactions and organ function is paramount for safe and effective cancer treatment.